Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

In a significant advancement for Parkinson’s Disease (PD) therapy, researchers have developed a targeted nano formulation ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...